Abstract
Recent research suggests an association between the development and progression of chronic kidney disease (CKD) - which affects 10–13% of the general population and leads to high rates of morbidity - and sleep apnea (SA).
SA impacts 2–4% of middle aged adults through one of its three forms: obstructive (OSA), central (CSA) and mixed sleep apnea, respectively. SA is associated with sleep fragmentation and hypoxemia during the apneic phenomena. Sleep fragmentation activates the renin-angiotensin-aldosterone system and the sympathetic nervous system, and alters the cardiovascular hemodynamic. It also results in the production of free radicals. SA is a risk factor for CKD progression because it is associated with glomerular hyper-filtration and may be an independent predictor of proteinuria. More specifically, the treatment of sleep apnea, manifested through one of its three forms - obstructive, central, and mixed, respectively - can reduce the severity of CKD and delay its progression by reducing CKD risk factors.
This paper discusses the mechanisms that link CKD and sleep apnea, and suggests SA treatments with beneficial effects to CKD-related cases. Optimizing sleep duration and quality and treating sleep disorders, especially SA, we can reduce the severity of CKD and the delay of progression.
Keywords: Sleep apnea, Hypertension, Renin-angiotensin-aldosterone system, Autonomic nervous system, Chronic kidney disease.
Current Respiratory Medicine Reviews
Title:The Links Between Sleep Apnea and Chronic Kidney Disease
Volume: 11 Issue: 4
Author(s): Marius Balint Gib, Christophe Aron, Svetlana Ilie, Frederic Wallyn, Macha Tetart and Dumitrita Balint Gib
Affiliation:
Keywords: Sleep apnea, Hypertension, Renin-angiotensin-aldosterone system, Autonomic nervous system, Chronic kidney disease.
Abstract: Recent research suggests an association between the development and progression of chronic kidney disease (CKD) - which affects 10–13% of the general population and leads to high rates of morbidity - and sleep apnea (SA).
SA impacts 2–4% of middle aged adults through one of its three forms: obstructive (OSA), central (CSA) and mixed sleep apnea, respectively. SA is associated with sleep fragmentation and hypoxemia during the apneic phenomena. Sleep fragmentation activates the renin-angiotensin-aldosterone system and the sympathetic nervous system, and alters the cardiovascular hemodynamic. It also results in the production of free radicals. SA is a risk factor for CKD progression because it is associated with glomerular hyper-filtration and may be an independent predictor of proteinuria. More specifically, the treatment of sleep apnea, manifested through one of its three forms - obstructive, central, and mixed, respectively - can reduce the severity of CKD and delay its progression by reducing CKD risk factors.
This paper discusses the mechanisms that link CKD and sleep apnea, and suggests SA treatments with beneficial effects to CKD-related cases. Optimizing sleep duration and quality and treating sleep disorders, especially SA, we can reduce the severity of CKD and the delay of progression.
Export Options
About this article
Cite this article as:
Gib Balint Marius, Aron Christophe, Ilie Svetlana, Wallyn Frederic, Tetart Macha and Balint Gib Dumitrita, The Links Between Sleep Apnea and Chronic Kidney Disease, Current Respiratory Medicine Reviews 2015; 11 (4) . https://dx.doi.org/10.2174/1573398X11666150915213824
DOI https://dx.doi.org/10.2174/1573398X11666150915213824 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interactions between Phytochemicals from Traditional Chinese Medicines and Human Cytochrome P450 Enzymes
Current Drug Metabolism GLP-1, Incretin Mimetics and DPP 4 Inhibitors: New Ways in the Treatment of Type 2 Diabetes
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents "Heart Failure: Meeting the Challenges of Surveillance and Knowledge Translation in Resource-poor Settings"
Current Cardiology Reviews Gene Electrotransfer to Skin; Review of Existing Literature and Clinical Perspectives
Current Gene Therapy Novel Targets of Metformin in Cardioprotection: Beyond the Effects Mediated by AMPK
Current Pharmaceutical Design Aldosterone Receptor Antagonists and Cardiovascular Disease: Do We Need a Change of the Guard?
Cardiovascular & Hematological Agents in Medicinal Chemistry Advanced Nanomedicines for the Treatment and Diagnosis of Myocardial Infarction and Heart Failure
Current Drug Targets Forkhead Genes: Their Role and Impact on Ocular Developmental Diseases
Current Genomics Cerebral Aneurysm as an Exacerbating Factor in Stroke Pathology and a Therapeutic Target for Neuroprotection
Current Pharmaceutical Design Role of miRNAs in Coronary Artery Disease
Current Signal Transduction Therapy The Role of SHP-2 in Cell Signalling and Human Disease
Current Enzyme Inhibition Cardio-Renal-Anemia Syndrome: A Link Between Erythropoietin, Dimethylarginine and Homocysteine
Current Medicinal Chemistry Thienopyridines and Statins: Assessing a Potential Drug-Drug Interaction
Current Pharmaceutical Design The Long Run: Neuroprotective Effects of Physical Exercise on Adult Neurogenesis from Youth to Old Age
Current Neuropharmacology Human Clinical Studies of Tea Polyphenols in Allergy or Life Style-related Diseases
Current Pharmaceutical Design Systemic Sclerosis: Clinical Manifestations
Current Rheumatology Reviews Hypoxia Inducible Factor 1 as a Therapeutic Target in Ischemic Stroke
Current Medicinal Chemistry Role of Curcumin in Modulating Plasma PON1 Arylesterase Activity and Susceptibility to LDL Oxidation in Oxidatively Challenged Wistar Rats
Letters in Drug Design & Discovery Statins in the Treatment of Acute Ischemic Stroke
Current Pharmaceutical Biotechnology Antioxidants Suppress Th1-Type Immune Response In Vitro
Drug Metabolism Letters